Non-autoimmune combined factor XIII A and B subunit deficiencies in rheumatoid arthritis patients treated with anti-interleukin-6 receptor monoclonal antibody (tocilizumab)-Reference-Cited by-同舟云学术

Non-autoimmune combined factor XIII A and B subunit deficiencies in rheumatoid arthritis patients treated with anti-interleukin-6 receptor monoclonal antibody (tocilizumab)

Published:2016-04 Issue: Volume:140 Page:100-105
ISSN:0049-3848
Container-title:Thrombosis Research
language:en
Short-container-title:Thrombosis Research

Author:

Souri Masayoshi,Mokuda Sho,Inanami Hiroshi,Osaki Tsukasa,Takasugi Kiyoshi,Ichinose Akitada

Publisher

Elsevier BV

Subject

Hematology

Reference39 articles.

1. Diagnosis and classification of factor XIII deficiencies;Kohler;J. Thromb. Haemost.,2011

2. Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control;Ichinose;Int. J. Hematol.,2012

3. A contribution to the pathology of acquired plasma factor XIII deficiency;Ballerini;Semin. Thromb. Hemost.,1985

4. Factor XIII deficiency: pathogenic mechanisms and clinical significance;Egbring;Semin. Thromb. Hemost.,1996

5. Hemorrhagic acquired factor XIII (13) deficiency and acquired hemorrhaphilia 13 revisited;Ichinose;Semin. Thromb. Hemost.,2011

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of tocilizumab-induced hypofibrinogenemia in rheumatology practice: a retrospective, real-life, single-center experience;Rheumatology International;2024-09-12

2. Clinical observation of hypofibrinogenemia induced by the treatment of tocilizumab in rheumatic diseases and exploration of risk factor for hypofibrinogenemia;Clinical Rheumatology;2024-03-18

3. SEVERE HYPOFIBRINOGENEMIA IN A PATIENT WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB: CASE-BASED REVIEW;Anti-Aging Eastern Europe;2023-12-30

4. Clinical observation of hypofibrinogenemia induced by the treatment of tocilizumab in rheumatic diseases and exploration of risk factor for hypofibrinogenemia;2023-09-13

5. A phase I study comparing the pharmacokinetics and safety of HS628 (tocilizumab biosimilar) and reference tocilizumab in healthy male subjects;Clinical and Translational Science;2023-07-18